Skip to main content

Advertisement

Table 1 Demographic, clinical and laboratory characteristics of HIV-infected patients included in the study and those positive for HLA-B*5701 allele

From: HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia

Variable Total HLA-B*5701-positive p
N = 902 n = 24
Sex, n (%)
 Male 750 (83.1%) 20 (83.3%)  
 Female 152 (16.9%) 4 (16.7%) 0,62
Age (years)
 Median (IQR) 29 (24–39) 36 (23–45)  
  < 20 71 (7.9%) 1 (4.2%) 0,43
 20–29 382 (42.4%) 9 (37.5%) 0,39
 30–39 226 (26.2%) 6 (25%) 0,61
 40–49 117 (12.9%) 4 (16.7%) 0,39
 50–59 73 (8.1%) 3 (12.5%) 0,31
  > 60 23 (2.5%) 1 (4.2%) 0,47
Race
 Afro-Colombian 54 (6.0%) 1 (4.2%) 0,58
 Caucasian 50 (5.5%) 2 (8.3%) 0,39
 Indigenous 5 (0.6%) 0 (0%) 0,87
 Mestizo 793 (87.9%) 21 (87.5%) 0,57
Region of origin
 Andean 259 (28.7%) 4 (16,7%) 0,14
 North 226 (25.1%) 2 (8,3%) 0,04
 Central 200 (22.2%) 12 (50%) 0,003
 Western 169 (18.7%) 5 (20,8%) 0,48
 Eastern 48 (5.3%) 1 (4,2%) 0,63
Time since HIV diagnosis (days)
 Median (IQR) 36 (21–74) 67 (28–429)  
  ≤ 30 367 (40.7%) 8 (33.3%) 0,31
 31–180 414 (45.9%) 6 (25%) 0,03
 181–360 39 (4.3%) 3 (12.5%) 0,09
 361–720 30 (3.3%) 3 (12.5%) 0,05
  > 720 52 (5.8%) 4 (16.7%) 0,05
Baseline CD4 cell count (cells/mm3)
 Median (IQR) 321 (177–504) 450 (360–638)  
  < 200 257 (28.4%) 2 (8.4%) 0,02
 200–499 419 (46.5%) 11 (45.8%) 0,56
  ≥ 500 226 (25.1%) 11 (45.8%) 0,02
Baseline HIV viral load (copies/mL)
 Median (IQR) 44,332 (11206–156,278) 9064 (2749–22,248)  
  < 40 14 (1.5%) 2 (8.3%) 0,06
 40–1000 48 (5.3%) 3 (12.5%) 0,14
 1001–10,000 145 (16.1%) 9 (37.5%) 0,01
 10,001–100,000 391 (43.4%) 8 (33.3%) 0,22
  > 100,000 304 (33.7%) 2 (8.3%) 0,004
CDC clinical stage at diagnosis
 A 613 (67.9%) 22 (91.7%) 0,007
 B 141 (15.6%) 0 (0%) 0,02
 C 148 (16.4%) 2 (8.3%) 0,22
  1. IQR interquartile range